[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Southern California\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":646},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,110,0,25,[9,39,66,100,128,147,173,196,227,253,286,308,327,356,383,402,426,449,474,500,530,548,571,596,616],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100520769","magestic-trial-mirna-in-detecting-active-germ-cell-tumors-in-early-suspected-and-metastatic-disease-trial-100520769",false,"NCT06060873","MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial","Phase II Trial of Serum Micro RNA-371 in Detecting Active Germ Cell Tumors in Patients With Suspected Regional Disease - (MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial)","Inclusion Criteria:\n\n* Primary tumor excised by radical inguinal orchiectomy and pathology consistent with GCT (seminoma or NSGCT)\n* Clinical stage of patient is either:\n\n  * Stage I pure seminoma OR stage I pure seminoma with isolated retroperitoneal relapse or Stage IIA\u002FB pure seminoma\n  * Stage I NSGCT OR stage I NSGCT with isolated retroperitoneal relapse or Stage IIA\u002FB NSGCT\n* For subjects with retroperitoneal lymphadenopathy: no lymph node \\>3 cm in greatest dimension with no more than 2 nodes enlarged\n* Axial abdominal\u002Fpelvic imaging (CT or MRI) and chest imaging (x-ray, CT or MRI) within 3 months of enrollment if stage I patient\n* Axial abdominal\u002Fpelvic imaging (CT or MRI) and chest imaging (x-ray, CT or MRI) within 8 weeks of enrollment if stage II patient\n* miRNA-371 can be drawn and sent for analysis at time of consent\n* Enrollment within 1 year after orchiectomy for stage I patients\n* Enrollment at any timepoint after orchiectomy for stage II patients\n* Retroperitoneal lymphadenopathy must be within an RPLND template\n* Biopsy of lymph node is not required, though if biopsy of the retroperitoneal node(s) was obtained, pathology must be consistent with GCT\n* Serum Alpha Feto Protein (AFP) \\\u003C50 ng\u002Fml, β-Human Chorionic Gonadotropin (β-HCG) 25 mIU\u002Fml within 42 days (6 weeks) of enrollment\n* Age ≥ 18 years\n* Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Second primary malignancy\n* Patients receiving any other investigational agent (s)\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements","MALE","18 Years",{"count":20,"type":21},418,"ESTIMATED","OBSERVATIONAL","This study evaluates the accuracy of blood-based biomarker testing to predict the presence of active testicular cancer.",[25],"Malignant Testicular Germ Cell Tumor","RECRUITING","2026-08-19",{"date":29,"type":30},"2026-08-20","ACTUAL",{"date":32,"type":30},"2023-06-08",{"date":34,"type":21},"2028-12-08",{"name":36,"class":37},"University of Southern California","OTHER",7,{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100635237","caring-for-dementia-caregivers-in-ethnic-immigrant-communities-100635237","NCT07550075","Caring for Dementia Caregivers in Ethnic Immigrant Communities","Inclusion Criteria:\n\nSelf-identified Korean American adults aged 18 or older Provide care for a family member with dementia as a primary caregiver Primary caregiver defined as providing a minimum of 10 hours per week of in-home caregiving to a family member Speak English less than \"very well\" Able to attend virtual classes using an electronic device with Internet access\n\nExclusion Criteria:\n\nIndividuals with severe depression (Patient Health Questionnaire \\[PHQ-9\\] score ≥ 20), as K-Savvy is not a mental health treatment program",true,"ALL",{"count":48,"type":21},150,"INTERVENTIONAL",[51],"NA","Many caregivers of people with Alzheimer's disease or other dementias-especially those in immigrant communities who don't speak English well-don't get access to helpful, proven support programs.\n\nTo address this, the investigative team adapted an existing caregiver support program (called the Savvy Caregiver Program) to better fit target group's culture and language. This new version, called K-Savvy, is a 6-week online program taught in Korean. In an earlier small study, K-Savvy worked well: caregivers found it helpful, were willing to use it, and showed fewer symptoms of depression.\n\nNow, the investigative team wants to study it more carefully to see how well it really works and why.\n\nThe study has two main goals:\n\nGoal 1:\n\nThe investigative team will measure whether K-Savvy improves caregivers' well-being-specifically whether it reduces stress and depression and helps them feel more positive about caregiving. The investigative team will also look at why it works, focusing on whether it changes how caregivers think about their situation (for example, feeling less overwhelmed and more confident).\n\nGoal 2:\n\nThe investigative team will talk directly with caregivers and program instructors to understand their experiences with K-Savvy. This will help the investigative team learn what worked well, what didn't, and why.",[54,55],"No Disease or Condition is Being Studied","Stress (Psychology)",[57],"K-Savvy","2026-08-18",{"date":29,"type":30},{"date":61,"type":30},"2026-06-01",{"date":63,"type":21},"2030-12-30",{"name":36,"class":37},1,{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":46,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":49,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":7},"100611717","mapt-protocol-fixation-versus-arthroplasty-surgical-treatments-for-early-recovery-after-hip-fracture-faster-hip-100611717","NCT07244211","MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)","Musculoskeletal Adaptive Platform Trial (MAPT): Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)","FASTER-HIP","Inclusion Criteria:\n\n* 60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture\n* The patient has a health condition affecting physical mobility.\n* Complete fracture of the femoral neck (AO\u002FOTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging.\n* Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction.\n* Low energy injury mechanism.\n* Surgeons with expertise in internal fixation and total hip arthroplasty or hemiarthroplasty are available to perform surgery.\n\nExclusion Criteria:\n\n* The patient is not clinically suitable for either compared treatment.\n* Expected injury survival of less than 12 months.\n* Terminal illness with expected survival of less than 12 months.\n* Incarceration.\n* Unable to obtain informed consent due to language barriers.\n* Unable to obtain informed consent because the legally authorized representative was unavailable.\n* Problems, in the judgment of the study personnel, with maintaining follow-up with the patient.\n* Currently enrolled in a study or intervention domain that does not permit co-enrollment.\n* Prior enrollment in the specific platform trial intervention domain.\n* Patient or legally authorized representative did not provide informed consent (declined participation).\n* Eligible patient or legally authorized representative was not approached within the screening window (missed participant).\n* Other reasons to exclude the patient, as approved by the data coordinating center.\n* Associated lower extremity injury that prevents post-operative weight-bearing.\n* Retained hardware around the hip that precludes either study treatment.\n* Infection around the hip (soft tissue or bone).\n* Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.\n* Injury did not occur within 21 days of screening.\n* Patient is too ill, in the judgment of the attending surgeon, for internal fixation.\n* Patient is too ill, in the judgment of the attending surgeon, for arthroplasty.","60 Years",{"count":76,"type":21},600,[51],"This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.",[80],"Femoral Neck Fractures",[82,83,84,85,86,87,88,89,90,91],"Minimally displaced femoral neck fractures","arthroplasty","hip fractures","femoral fractures","orthopaedic procedures","older adults","patient-centered outcomes","adaptive trial","internal fixation","pragmatic trial","2026-08-06",{"date":94,"type":30},"2026-08-10",{"date":96,"type":30},"2026-01-23",{"date":98,"type":21},"2030-01-31",{"name":36,"class":37},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":46,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":49,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},"100651064","stroke-volume-based-fluid-resuscitation-in-ap-100651064","NCT07756476","Stroke Volume-based Fluid Resuscitation in AP","Stroke volUme-baSed Fluid resusciTAtIoN in AP (SUSTAIN)","SUSTAIN","Inclusion Criteria:\n\n* Patients between the age of 18-75\n* Predicted moderate and severe acute pancreatitis, which will be defined by the presence of SIRs, within 24 hours of enrollment\n\nExclusion Criteria:\n\n* Patients with the inability to preform a straight leg raise (i.e amputation)\n* Patients with high risk of adverse event related to fluid resuscitation\n* NYHA Class \\>= II Heart Failure\n* Child's B and C Cirrhosis\n* Dialysis Requirement\n* Clinical signs of hypervolemia, including pulmonary congestion (i.e dyspnea, pulmonary crackles on exam, interstitual edema on imaging) and ascites\n* Ages \\\u003C18 years old\n* Pregnant\n* Incarcerated\n* Unable to provide informed consent","75 Years",{"count":110,"type":21},80,[51],"The SUSTAIN Trial is a randomized control trial that allows for the control of aggressive hydration that is currently used in an inpatient setting, which can result is fluid overload in certain patients. With the impression that changes in stroke volume in individual patient will further improve the outcome.",[114],"Acute Pancreatitis (AP)",[116,117,118,119],"Acute Pancreatitis","Fluid Resuscitation","Pancreatitis","Stroke Volume","2026-08-05",{"date":94,"type":30},{"date":123,"type":30},"2026-03-19",{"date":125,"type":21},"2028-09-19",{"name":36,"class":37},2,{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":134,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":65},"100614436","gyn-aide-gynecologic-oncology-navigation-through-ai-driven-education-100614436","NCT07279571","GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education","AI-chatbot Evaluation (Aim 1):\n\nInclusion Criteria:\n\n* Patient of the LA General gynecologic oncology clinic\n* Age 18 years or older\n* Previously obtained the HPV vaccination (initial chatbot evaluation)\n* Eligible for HPV vaccination (pilot intervention; age \\\u003C46)\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Patients who do not speak English or Spanish\n* Patients who do not provide informed consent\n\nHPV vaccination rate (Aim 2):\n\nInclusion Criteria:\n\n* Patient of the LA General gynecologic oncology clinic\n* Age 18 years or older\n* Obtained the HPV vaccine\n\nExclusion Criteria:\n\n* None","FEMALE",{"count":136,"type":21},48,"This study seeks to understand how endometrial cancer patients get medical information about cancer care and their satisfaction with those health-seeking methods. It also assesses patient interest in using an artificial intelligence educational resource.",[139],"Gynecologic Disease","2026-08-03",{"date":92,"type":30},{"date":143,"type":30},"2026-06-12",{"date":145,"type":21},"2028-06-09",{"name":36,"class":37},{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":45,"sex":46,"minAge":155,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":49,"phases":158,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":65},"100534016","phase-2-mindfulness-assisted-psychedelic-therapy-100534016","NCT06233344","Mindfulness-Assisted Psychedelic Therapy","An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy","MAPT","Eligible participants will be:\n\n* Adults of any race, ethnicity, or gender who are age 25 years or older\n* Have not had formal mindfulness training\n* Have not previously used classic psychedelics\n* Agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that he\u002Fshe consumes on a usual morning, before arriving at the research unit on the morning of the drug session day. If the participant does not routinely consume caffeinated beverages, he\u002Fshe must agree not to do so on the session day.\n* Agree to refrain from using any psychoactive drugs, including alcoholic beverages and nicotine, within 24 hours of each drug administration. The exception is caffeine.\n* Agree not to take any PRN medications on the mornings of drug sessions\n* Agree not to take sildenafil (Viagra®), tadalafil, or similar medications within 72 hours of psilocybin administration.\n* Agree that for one week before the drug session, he\u002Fshe will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the study investigators. Exceptions will be evaluated by the study investigators and will include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals.\n\nParticipants will be excluded if they present with any of the following:\n\n* Prior exposure to formal mindfulness or meditation training\n* Previous use of psilocybin or other psychedelic drugs (LSD, mescaline, DMT\u002Fayahuasca, 5-methoxy-DMT)\n* Current use of tricyclic antidepressants, serotonin reuptake inhibitors, antipsychotics, atypical antipsychotics, monoamine oxidase inhibitors (MAOIs), mood stabilizers (lithium), buspirone, mirtazapine, trazodone, or other drugs that modulate the serotonin system. For individuals who have intermittent or PRN use of such medications, psilocybin sessions will not be conducted until at least 5 half-lives of the agent have elapsed after the last dose.\n* Current use of St. John's Wort or 5-hydroxytryptophan\n* Currently taking psychoactive prescription medication on a regular (e.g., daily) basis\n* Current or lifetime history of schizophrenia, other psychotic disorders, or bipolar I or II disorder; or a first or second degree relative with one of these disorders\n* Current or recent past (within the past 5 years) history of alcohol or drug dependence (other than caffeine or nicotine) or major depressive episode\n* Current or recent suicidal ideation (within the past month) or behavior (within the past 6 months), as assessed by a response of \"yes\" to any of questions in the \"Suicidal Ideation\" or \"Suicidal Behavior\" on the C-SSRS at the eligibility screen or baseline session\n* Current (past two weeks) self-reported risky alcohol use (\\>7 drinks\u002Fweek for women or \\>14 drinks\u002Fweek for men)\n* Current obsessive-compulsive disorder, dysthymic disorder, panic disorder, dissociative disorder, anorexia nervosa, or bulimia nervosa\n* Has a psychiatric condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin\n* Self-reported use of or positive urine drug screen for amphetamines\u002Fmethamphetamine, opioids, barbiturates, methadone, cocaine, or PCP at the eligibility screen visit or the psilocybin visit\n* Positive breath alcohol test at the eligibility screen visit or the psilocybin visit (BrAC \\> 0.01)\n* Current pregnancy, planned pregnancy in the next 6 months (at phone screen or eligibility screen), positive urine pregnancy test (for participants of childbearing potential) at the eligibility screen or the psilocybin session, or current breastfeeding\n* Unwilling to use a medically-accepted highly effective form of birth control (such as hormonal implants, intrauterine devices (IUDs), hormonal birth control pills, surgical sterility, or other methods deemed highly effective (\\\u003C1% failure rate) by the study physician) during the study (applies to male participants as well as female participants of childbearing potential)\n* Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled hypertension, a clinically significant ECG abnormality (e.g., atrial fibrillation, QTc greater than 450 msec), artificial heart valve, or TIA in the past year\n* Epilepsy with history of seizures\n* Current unstable medical condition (including uncontrolled or poorly controlled hypertension - resting blood pressure greater than 140 (systolic) or 90 (diastolic) mmHg at the eligibility screening will be reviewed by the study physician and participants with stable hypertension will be asked to follow-up with their primary care physician to initiate appropriate hypertensive treatment prior to proceeding)\n* Diabetes (type 1 or 2) with insulin dependence; if taking oral hypoglycemic agent, then no history of hypoglycemia\n* Any other medical condition that may be incompatible with safe exposure to psilocybin\n* Inability to speak English\n* Inability to provide informed consent","25 Years",{"count":157,"type":21},40,[159],"PHASE2","The goal of this clinical trial is to test psilocybin in combination with mindfulness training in healthy adults. The main question it aims to answer is \"Does mindfulness training enhance the effects of psychedelic therapy (psilocybin) on mental health?\" Interested individuals will complete an initial eligibility session and eligible participants will then be randomized into one of two groups: one dose of psilocybin (administered under the supervision of study therapists) combined with 8 weeks of weekly mindfulness training classes (Arm 1) or psilocybin alone (Arm 2). Both groups will complete baseline and post-treatment assessment sessions where they will complete questionnaires, computerized cognitive tests, and have an EEG (a measure of electrical activity in the brain) and functional MRI of brain if possible. Both groups will also complete 2 follow-up surveys (at \\~8 weeks, and 1 year after the post-treatment assessment) either online through REDCap or by phone or video call with a research assistant.",[162],"Mental Health",[164,165,166],"Psychedelic therapy","Psilocybin","Mindfulness",{"date":92,"type":30},{"date":169,"type":30},"2025-07-30",{"date":171,"type":21},"2028-08",{"name":36,"class":37},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":134,"minAge":18,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":49,"phases":183,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":65},"100569963","phase-4-evaluation-of-a-long-versus-short-clomid-protocol-for-controlled-ovarian-stimulation-100569963","NCT06701071","Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation","Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation in Patients With Diminished Ovarian Reserve Undergoing In-vitro Fertilization: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Undergoing IVF\n* Must meet POSEIDON criteria based on clinic evaluation\n* Female partner: Antral follicle count of 2 or more and age \\\u003C45 at time of stimulation start\n* Male partner\u002Fsperm source: Cannot be azoospermic\n* Planning freeze-all cycle (regardless of blastocyst or cleavage stage culture) or fresh transfer if randomized to short Clomid group\n* Planning 36-hour trigger window\n\nExclusion Criteria:\n\n* Normal ovarian reserve or good response\n* Allergy or adverse reaction to Clomid\n* Minimal stimulation protocols\n* History of prior premature ovulation","44 Years",{"count":182,"type":21},120,[184],"PHASE4","The goal of this clinical trial is to evaluate a long Clomid protocol as compared to a 5-day Clomid protocol for ovarian stimulation in patients with diminished ovarian reserve undergoing ovarian stimulation for in-vitro fertilization. The aim of the long Clomid protocol is to intensify stimulation of the ovaries and reduce both cost and injection burden for patients. Participants will be randomized to receive the long Clomid protocol vs. the typical protocol involving Clomid only for 5 days followed by growth hormone-releasing hormone (GnRH) antagonist. The primary outcome the investigators will evaluate will be the number of mature eggs retrieved.",[187],"Infertility, Female","2026-07-31",{"date":190,"type":30},"2026-08-04",{"date":192,"type":30},"2025-06-01",{"date":194,"type":21},"2028-06",{"name":36,"class":37},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":46,"minAge":74,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":49,"phases":205,"briefSummary":206,"conditions":207,"keywords":212,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":226},"100554267","early-internal-fixation-versus-nonoperative-care-with-early-rehabilitation-for-lc1-fragility-fractures-of-the-pelvis-100554267","NCT06496867","Early Internal Fixation Versus NonOperative Care With Early Rehabilitation for LC1 Fragility Fractures of the Pelvis","Multicenter Randomized Controlled Trial Comparing Early Internal Fixation Versus NonOperative Care With Early Rehabilitation for LC1 Fragility Fractures of the Pelvis: A Pilot Study","PIVOT-LC1-Pi","Inclusion Criteria:\n\n1. Patient 60 years of age or older.\n2. Low energy injury mechanism defined as a fall from standing height.\n3. LC1 pelvis fracture (AO\u002FOTA 61B1.1 or 61B2.1) confirmed with antero-posterior, inlet, and outlet pelvis radiographs, computed tomography, or magnetic resonance imaging.\n4. Fracture pattern that could be, in the judgment of the attending surgeon, managed with either early internal fixation or nonoperative care with early rehabilitation.\n5. Fracture displacement of \\\u003C10 mm of the posterior pelvic ring on computed tomography of the pelvis.\n6. Injury occurred within 21 days of screening.\n\nExclusion Criteria:\n\n1. Patient did not ambulate prior to injury.\n2. Patient has another condition, injury, or fracture that prevents post-operative weightbearing on any extremity.\n3. Retained implants around the pelvis that precludes or limits either study treatment.\n4. Infection around the hip (soft tissue or bone).\n5. Pathologic fracture with a lytic lesion in the pelvis or sacrum that precludes internal fixation.\n6. Patient is too ill, in the judgement of the attending surgeon, for internal fixation.\n7. Patient is too ill, in the judgement of the attending surgeon, for nonoperative care.\n8. Problems, in the judgment of study personnel, with maintaining follow-up with the patient.\n9. Expected injury survival of less than 12 months.\n10. Terminal illness with expected survival of less than 12 months.\n11. Currently enrolled in a study that does not permit co-enrollment.\n12. Prior enrollment in the trial.\n13. Unable to obtain informed consent due to language barriers.\n14. Unable to obtain informed consent because a legally authorized representative (LAR) was unavailable.\n15. Did not provide informed consent (declined participation).\n16. Patient or LAR not approached to participate in the trial (missed patient).\n17. Other reason to exclude the patient, as approved by the Methods Centre.",{"count":136,"type":21},[51],"The goal of this randomized pilot study is to assess feasibility of the trial and to collect information to inform the design of a definitive trial. Adult patients ages 60 years or older with a low-energy lateral compression type 1 (LC1) pelvis fracture with \\\u003C10 mm initial displacement of the posterior pelvic ring will be eligible to participate in the study. Patients will be randomized to one of two treatment groups, early internal fixation or nonoperative care with early rehabilitation, defined as at least five days of attempted mobilization by rehabilitation providers. Participants will be followed for 1 year.",[208,209,210,211],"Multiple Closed Pelvic Fractures With Disruption of Pelvic Ring","Fragility Fracture","Internal Fixation","Nonoperative Care",[209,213,214,215,210,211,216,217],"Lateral Compression type 1","Pelvis Fracture","Older Adults","Physical Therapy","Early","2026-07-22",{"date":220,"type":30},"2026-07-24",{"date":222,"type":30},"2024-11-12",{"date":224,"type":21},"2027-12-31",{"name":36,"class":37},13,{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":45,"sex":46,"minAge":235,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":49,"phases":239,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":65},"100648548","social-media-influences-on-engagement-and-susceptibility-to-non-combustible-tobacco-product-use-among-youth-and-young-adults-aya-100648548","NCT07721883","Social Media Influences on Engagement and Susceptibility to Non-combustible Tobacco Product Use Among Youth and Young Adults (AYA)","USC Tobacco Center of Regulatory Science - Project 4: Social Media Influences on Engagement and Susceptibility to Non-combustible Tobacco Product Use Among Youth and Young Adults (AYA)","USC TCORS P4","Inclusion Criteria:\n\n* High school student\n* Provides parental consent and youth assent\n\nExclusion Criteria:\n\n* No parental consent or youth assent\n* Can't read or speak English","14 Years","17 Years",{"count":238,"type":21},4500,[51],"The purpose of this study is to present social media posts with varying combinations of flavor types and mentions of stealth use, to adolescents and determine whether these message characteristics increase adolescents' perceptions of these products and susceptibility to using these products.",[242],"Perceptions of Tobacco Products",[244],"tobacco, e-cigarette, social media","2026-07-20",{"date":247,"type":30},"2026-07-23",{"date":249,"type":30},"2025-07-01",{"date":251,"type":21},"2028-05-01",{"name":36,"class":37},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":45,"sex":134,"minAge":18,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":49,"phases":262,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":127},"100602896","phase-1-hyperemesis-gravidarum-risk-reduction-with-metformin-100602896","NCT07129473","Hyperemesis Gravidarum Risk Reduction With Metformin","Inclusion Criteria:\n\n* Ages 18-49\n* HG in prior pregnancy (clinical criteria: intravenous (IV) fluid treatment)\n* Trying to conceive\n* Treatment Arm: willing to refrain from trying to conceive during their metformin dose titration period and before 2 weeks at maximum tolerated dose (up to 8 weeks total). Will use birth control or contraceptive device until maintenance dose.\n* Under care of a personal OB\u002FGYN or willing to establish care with a personal OB\u002FGYN before study start\n* Ownership of a personal scale (or willingness to obtain one for study use)\n* Willing to participate in a trial that includes daily use of an oral agent prior to pregnancy\n* Treatment Arm: residing in California\u002FAlabama\n* Treatment Arm: normal blood panel (CBC) (e.g., white count, hemoglobin, platelets all within the normal range)\n* Treatment Arm: normal to mildly decreased creatinine levels (estimated GFR \\> 60 mL\u002Fmin\u002F1.73m²)\n* Survey\u002FComparator Arm: not currently taking metformin and do not plan to take metformin prior to pregnancy\n* Able and willing to provide written informed consent prior to initiation of any study procedures.\n* Demonstrates understanding of the study objectives, requirements, potential risks, and willingness to comply with study procedures and follow-up.\n* English speaking\n* Regular cycles\n\nExclusion Criteria:\n\n* Allergic or adverse reaction to metformin-XR\n* Thalassemia\n* Cirrhosis and\u002For hepatic impairment\n* Decompensated heart failure\n* Daily\u002Fregular use of medications\u002Fsubstances (tobacco, cyclobenzaprine, cannabis, escitalopram, sertraline, other SSRIs, Lasix)\n* Treatment Arm: Use of insulin, sulfonylureas, meglitinides, or other blood sugar altering medication\n* Assisted Reproductive Technology\n* Excess alcohol consumption (\\> 7 standard drinks per week on average)\n* Pregnant\n* Not trying to conceive\n* Treatment Arm: Residing outside California\u002FAlabama\n* Treatment Arm: abnormal blood panel (CBC) (e.g., white count or platelets not within the normal range)\n* Treatment Arm: abnormal creatinine levels (estimated GFR \\\u003C 60 mL\u002Fmin\u002F1.73m² excluded from the study, signs of kidney disease)\n* Treatment Arm: current metformin use\n* Survey\u002FComparator Arm: current metformin use or plans to take metformin prior to pregnancy\n* Any medical\u002Fsurgical condition that the investigator feels would compromise the participant's participation in the study\n* Not able and willing to provide written informed consent prior to initiation of any study procedures.\n* Does not demonstrate understanding of the study objectives, requirements, potential risks, and willingness to comply with study procedures and follow-up.\n* Not english speaking\n* Irregular cycles\n* Not willing to refrain from trying to conceive\u002Fuse birth control or contraceptive device until maintenance dose.","49 Years",{"count":261,"type":21},224,[263,159],"PHASE1","The goal of this clinical trial is to evaluate whether daily oral metformin extended-release (metformin-XR), taken prior to and in early pregnancy, can reduce the risk and severity of Hyperemesis Gravidarum (HG), a severe nausea and vomiting condition in pregnancy, in individuals aged 18-49 who have experienced HG in a previous pregnancy and are trying to conceive. Researchers also aim to better understand which individuals may respond well - or poorly - to metformin based on biological and clinical characteristics.\n\nThe main questions this study aims to answer are:\n\n1. Is metformin-XR well-tolerated when taken by non-pregnant individuals who have had HG in a previous pregnancy and are currently trying to conceive?\n2. How safe and tolerable is metformin-XR when taken at increasing doses over an 8-week titration period and continued through early pregnancy (or for up to 12 months after reaching maintenance dose if pregnancy does not occur)?\n3. Among those who become pregnant during the study, does pre-pregnancy metformin-XR use reduce the risk of HG coming back and lower the severity of nausea and vomiting symptoms?\n4. How does pre-pregnancy metformin-XR use affect pregnancy outcomes, postpartum health, and newborn health and development?\n5. Are there specific genetic, biomarker, demographic, or clinical features that predict whether someone is likely to benefit from metformin-XR or experience side effects that lead them to stop taking it?\n\nResearchers will compare a metformin treatment group to a survey-only group (comparator, no study drug) to see if metformin-XR is associated with improved outcomes, including reduced HG recurrence and better maternal and neonatal health indicators.\n\nParticipants will:\n\nComplete online questionnaires before pregnancy, during early pregnancy, and postpartum\n\n(Treatment group only) Take daily metformin-XR and attend three brief study visits\n\n(Treatment group only) Undergo blood draws at specified timepoints to assess safety and biological response",[266],"Hyperemesis Gravidarum",[268,269,270,266,271,272,273,274,275,276,277,278,279],"Metformin","HG","Hyperemesis","Nausea and Vomiting of Pregnancy","NVP","severe Nausea and Vomiting of Pregnancy","sNVP","Nausea","Vomiting","Pregnancy","Pregnant","Morning Sickness",{"date":218,"type":30},{"date":282,"type":30},"2026-07-13",{"date":284,"type":21},"2031-03",{"name":36,"class":37},{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":45,"sex":46,"minAge":293,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":49,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":307,"locationsCount":127},"100648233","tactile-pre-visit-imagery-100648233","NCT07719205","Tactile Pre-Visit Imagery","Tactile Pre-Visit Imagery Effect on Behavior of Children During Dental Procedures","Inclusion Criteria:\n\n* Children aged 4-10 years\n* ASA I or II\n* Patients who have NOT had dental treatment before\n* Patients needing at least ONE composite filling or stainless steel crown \\[CP1\\] with nitrous oxide and local anesthesia (composite filling must be done at the first treatment visit)\n* Parents and children must speak English or Spanish\n\nExclusion Criteria:\n\n* Children with developmental delays or cognitive impairments that may impact their ability to participate in pre-visit imagery activities\n* Patients with visual or tactile disabilities associated for a particular medical condition or as reported on their medical history form\n* Patients who refuse to wear nitrous hood\n* Emergency dental appointments","4 Years","10 Years",{"count":296,"type":21},100,[51],"In pediatric dentistry, our primary goals are to prevent dental caries and, when necessary, provide treatment in a safe and comforting environment that minimizes anxiety for young patients. By familiarizing young patients with the steps involved in common dental procedures, tactile pre-visit imagery booklets can reduce the fear of the unknown.\n\nStudy Objective\u002FPurpose: The purpose of this study is to determine whether tactile pre-visit imagery could reduce dental anxiety and fear in pediatric patients prior to their first restorative procedure. An additional aspect of this study entails assessing the patient's behavior and determining if it improves with the use of a tactile pre-visit imagery booklet.",[300,301],"Dental Anxiety in Children","Behavior Change","2026-07-17",{"date":218,"type":30},{"date":305,"type":30},"2026-01-15",{"date":194,"type":21},{"name":36,"class":37},{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":46,"minAge":235,"maxAge":236,"enrollmentInfo":315,"targetDuration":4,"studyType":49,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":321,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":326,"locationsCount":65},"100645424","e-cigarette-social-media-marketing-and-its-perceptions-by-youth-100645424","NCT07694739","E-cigarette Social Media Marketing and Its Perceptions by Youth","Evolution of Influencer-driven E-cigarette Marketing on Social Media and Its Effect on E-cigarette Perceptions and Use Patterns Among Adolescents","Inclusion Criteria:\n\n* 14-17 years of age,\n* English fluency,\n\nExclusion Criteria:\n\nNot meeting the following criteria:\n\n* 14-17 years of age,\n* English fluency,",{"count":316,"type":21},6000,[51],"The proposed study will conduct two randomized between-subject experiments among 6,000 adolescents (per each experiment) recruited nationwide to test the effects of audio-visual features of e-cigarette influencer marketing on perceptions of influencer credibility, e-cigarette harm perceptions, appeal, and susceptibility to e-cigarette use. This protocol represent the first experiment.",[320],"Vaping","NOT_YET_RECRUITING",{"date":245,"type":30},{"date":324,"type":21},"2027-01-01",{"date":63,"type":21},{"name":36,"class":37},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":46,"minAge":334,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":49,"phases":338,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":355},"100641102","phase-2-multi-site-trial-of-tirzepatide-for-smoking-cessation-100641102","NCT07602699","Multi-Site Trial of Tirzepatide for Smoking Cessation","A Multi-Site Trial of Tirzepatide for Smoking Cessation","Inclusion Criteria:\n\n1. Age 21-65 years\n2. Body mass index ≥ 25kg\u002Fm2 at the baseline screening\n3. Reporting ≥10 cigarettes per day, on average, for the past 6 months and \\> 2 year duration of smoking\n4. Interest in making a long-term cessation attempt within the next 30-60 days\n5. Willingness to receive study medication and standard-of-care smoking cessation supports (nicotine replacement therapy and a smoking cessation app)\n6. Ability to adhere to weekly visits and study procedures over the study period (i.e., no plans to move or travel for extended periods)\n7. Exhaled CO of \\>5ppm at baseline\n8. Use of an acceptable birth control method for female participants\\*\n9. Ability to read and communicate in English\n\nExclusion Criteria:\n\n1. BMI \\\u003C 25 kg\u002Fm2 at screening\n2. History of diabetes, diabetes-attributable medical conditions, or HbA1c ≥6.5% at baseline\n3. Recent (past 90 days) active suicidal ideation or lifetime history of suicide attempt\n4. Current treatment for psychotic disorders or mood disorders with psychotic features (e.g., schizophrenia, schizoaffective disorder, depression with psychotic features), current treatment for bipolar disorder (with or without psychotic features), or current secondary psychosis due to substance use or another medical condition\n5. Meeting DSM-5 criteria for a current (past 12 months) substance use disorder other than tobacco use disorder, mild or moderate cannabis use disorder, or mild or moderate alcohol use disorder.\n6. Recent (past 30 day) self-report of illicit drug use (excluding cannabis) or non-prescribed opioids; or positive urine screen for illicit drugs. A positive screen for opioids will be allowed if the participant is prescribed an opioid replacement therapy medication and can provide documentation.\n7. Past 30-day initiation of psychiatric medications (e.g., SSRIs) or changes to medication dose\n8. Treatment with tirzepatide or another GLP-1RA medication in the prior 6 months\n9. Current (past month) treatment with other weight loss, diabetes, or smoking cessation medications (varenicline or bupropion; excluding nicotine replacement products)\n10. Severe GI disease (e.g., gastroparesis, ulcerative colitis).\n11. History of gastric bypass surgery or other surgeries of the stomach\n12. Any health condition or treatment\u002Fmedication that would preclude the use of tirzepatide or NRT, in the opinion of the study physician, including severe cardiovascular disease\n13. History of chronic pancreatitis or acute pancreatitis in the last 6 months\n14. Currently nursing, pregnant, or anticipating pregnancy\n15. History of diabetic retinopathy, proliferative retinopathy, or maculopathy\n16. Elevated serum lipase, amylase, bilirubin, or ALP, ALT, or AST (\\>5x upper limit of normal range)\n17. History of malignant neoplasms in the last 5 years, except non-melanoma skin cancer\n18. Inability to attend weekly clinic visits as scheduled (i.e., based on travel or work schedule)\n19. Currently enrolled in another clinical study involving an investigational product\n20. Currently living in the same household as someone taking a GLP-1 medication, or living with a current or former participant in the present trial\n21. Planned surgical procedures requiring anesthesia during the planned study medication period\n22. Personal or family history of medullary thyroid cancer\n23. Personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN 2)\n24. Treatment with other weight loss (e.g., phentermine), or FDA-approved, non-NRT smoking cessation therapies (varenicline, bupropion) or FDA-approved AUD medications (naltrexone, acamprosate, disulfiram) or off-label AUD medications (e.g., topiramate) in the past 90 days\n25. Any health condition or treatment\u002Fmedication that would preclude use of tirzepatide or NRT, in the opinion of the site physicians including thyroid enlargement.","21 Years","65 Years",{"count":337,"type":21},300,[159],"This multi-site clinical trial will generate data on the efficacy of tirzepatide for smoking cessation and associated outcomes (e.g., post-cessation weight gain) in treatment-seeking people who smoke (PWS) with overweight or obesity. A sample of 300 treatment-seeking people who smoke with body mass index of 25 kg\u002Fm2 or greater will be recruited from four geographic sites (University of Southern California, Yale University, University of Chicago, and University of Colorado Anschutz Medical Campus) to participate in a parallel-arm, dose-escalating, placebo-controlled trial. Participants will attend weekly clinic visits to receive subcutaneous tirzepatide or placebo over 16 weeks (Visit Weeks 1-16), followed by follow-up visits at Week 17 and Week 27. Medication will be prescribed according to the standard dose titration schedule for the first 16 weeks of treatment (initial dose: 2.5mg\u002Fweek; final dose: 10mg\u002Fweek). All participants will also receive nicotine patches.",[341,342],"Smoking Cessation","Smoking Behaviors",[344,345,346,347],"Addiction","GLP-1","Tirzepatide","Substance Use Disorder","2026-07-15",{"date":302,"type":30},{"date":351,"type":30},"2026-06-05",{"date":353,"type":21},"2028-09",{"name":36,"class":37},4,{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":45,"sex":46,"minAge":334,"maxAge":363,"enrollmentInfo":364,"targetDuration":4,"studyType":49,"phases":366,"briefSummary":367,"conditions":368,"keywords":370,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":65},"100645945","braincraving-response-to-smoking-cues-after-oral-nicotine-pouch-use-100645945","NCT07698470","Brain\u002FCraving Response to Smoking Cues After Oral Nicotine Pouch Use","Cue-Exposure Response Evaluation: Brain Reactivity to ONPs","Inclusion Criteria:\n\n* Age 21 years - 55 years\n* Self-reported use of cigarettes within the past 30 days\n* Biochemical confirmation of cigarette use:\n\n  o Carbon monoxide (CO) breath sample ≥10 ppm\n* Fagerström Test for Nicotine Dependence (FTND) score ≥5, indicating moderate to high nicotine dependence\n* Fluent in English\n* Willing to try an oral nicotine pouch\n* Willing to abstain from nicotine for at least 12 hours prior to each experimental session\n\nExclusion Criteria:\n\n* Age younger than 21 years or older than 55 years\n* Biochemical evidence inconsistent with recent cigarette use:\n\n  o CO breath sample \\\u003C10 ppm\n* Expressed intent to reduce or quit nicotine use within the next 30 days\n* History of medical conditions contraindicated for nicotine use (e.g., uncontrolled hypertension, recent cardiac events)\n* Primary use of non-cigarette products (e.g., cigars, pipe tobacco, smokeless tobacco)\n* Prior use of oral nicotine products in their lifetime","55 Years",{"count":365,"type":21},45,[51],"Oral nicotine pouches (ONPs) are non-combustible nicotine products that may reduce cigarette craving and smoking cue-induced brain activity, supporting their potential as harm-reduction tools for adults who smoke cigarettes. This within-subject, repeated-measures study will evaluate the acute effects of a single 6 mg oral nicotine pouch on subjective craving and prefrontal neural responses to smoking-related cues using functional near-infrared spectroscopy (fNIRS). Participants will complete assessments before and after nicotine pouch administration following overnight nicotine abstinence to characterize changes in craving and neural cue reactivity.",[369],"Nicotine Dependence",[371,372,373,374,375],"Oral Nicotine Pouches","Oral Nicotine Products","Smoking","Cigarettes","Harm Reduction","2026-07-07",{"date":282,"type":30},{"date":379,"type":30},"2026-04-30",{"date":381,"type":21},"2027-08",{"name":36,"class":37},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":45,"sex":46,"minAge":334,"maxAge":155,"enrollmentInfo":390,"targetDuration":4,"studyType":49,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":127},"100554982","abuse-liability-and-appeal-of-oral-nicotine-products-100554982","NCT06506162","Abuse Liability and Appeal of Oral Nicotine Products","The Effect of Flavor and Nicotine Strength on the Abuse Liability and Appeal of Oral Nicotine Products","Inclusion Criteria:\n\n1. aged 21-25 years\n2. current exclusive EC user (defined as at least weekly use over the past 3 months) and recent nicotine use confirmed by positive urine test (\\>1 semiquantitative Total Nicotine Equivalent; see below)\n3. not currently using another tobacco\u002Fnicotine product (defined as no use in the past 6 months)\n4. have never used any ONP (medicinal or nonmedicinal)\n5. willing to try study provided ONPs.\n\nExclusion Criteria:\n\n1. recent COVID-19+ (positive test in the past 30 days)\n2. a recent COVID-19 hospitalization (past 3 months)\n3. unstable or significant psychiatric conditions (past and stable conditions allowed)\n4. history of cardiac event or distress within the past 3 months\n5. currently pregnant (based on urine pregnancy test), planning to become pregnant, or breastfeeding.",{"count":391,"type":21},320,[51],"There has been a recent proliferation of novel oral nicotine products (ONPs) brought to market, including new nicotine gums and pouches. Unlike electronic cigarettes (ECs) ONPs have no impending regulatory barriers with regard to flavoring or nicotine dose, and manufacturers have capitalized on this by introducing an extensive slate of characterizing flavors and nicotine concentrations. Both sales trajectory and the surge in marketing suggest ONP use is likely to increase in the coming years. Work by the investigators and others indicates that interest in these products is high among current EC users, and among specific demographic groups including those who identify as sexual and gender minority (SGM). ONP use is discrete and so can function as a secondary source of nicotine, encouraging dual use patterns and more severe nicotine dependence. Depending on the use patterns of ONPs that emerge, regulation of ONPs may serve the public health interest. However, very little is known about factors relevant to the actual appeal and abuse liability of these products. The investigators propose to address this important gap by assessing the appeal and abuse liability of gum and pouch ONPs as a function of flavor (mint vs fruit) and nicotine concentration (2mg vs. 4mg). Flavor and nicotine strength, along with product type, are regulatable attributes, and so it is essential to understand their impact on appeal and abuse liability. Evidence from EC use suggests a potential interaction between flavor and nicotine strength, with flavorants in the \"mint\" category desensitizing receptors integral to the aversive sensory experience of nicotine, leading to greater tolerability of high nicotine concentration. Because of current ONP marketing emphasis on youth, the investigators will recruit young adult exclusive EC users (N = 320; ages 21 - 25). The investigators will target recruitment of a sufficient number of SGM participants (N = 64, 20% of sample) to allow assessment of potential differentiation of this group. Participants will complete one virtual session focused on assessment of the sensory appeal of ONPs. Based on individual participant ratings, the preferred fruit and the preferred mint ONP will be selected (from their randomized product type and nicotine strength) to each be assessed in a single-product session examining factors known to predict abuse liability (relief of withdrawal, liking, behavioral economic indices of demand, and follow-up naturalistic product use). The investigators will pay particular attention to evidence suggesting dual use potential of ONPs, given its association with greater severity of nicotine dependence. The proposed work will inform efforts to mitigate ONPs potential to promote dual-use and more severe nicotine dependence among young adult EC users, by isolating the impact of potential regulatory targets.",[369],{"date":396,"type":30},"2026-07-09",{"date":398,"type":30},"2024-02-09",{"date":400,"type":21},"2028-02-14",{"name":36,"class":37},{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":45,"sex":46,"minAge":410,"maxAge":235,"enrollmentInfo":411,"targetDuration":4,"studyType":49,"phases":413,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":65},"100542391","phase-1-coes-curing-order-effects-on-sealants-100542391","NCT06342258","COES: Curing Order Effects on Sealants","Effects of Cured Bond On Sealant Retention In The Pediatric Population","COES","Inclusion Criteria:\n\n* ASA I and ASA II children, aged 5 to 14 years who are patients of CDHC and USC with adequate eruption of permanent first or second molars for placement of sealants\n* These teeth will not have previous restorations, interproximal lesions, pathology, or occlusal lesions.\n* Behavior of the children should be within a Frankl 3 or 4 category, indicating a \"positive\" and \"Definitely Positive\" behavior rating, which would allow for safe and controlled execution of the proposed protocol\n* Patient must have contralateral molars in the same arch in which sealants can be placed. For example a child with #30 and #19 present will qualify for the study.\n\nExclusion Criteria\n\n* Any tooth with previous sealant placement\n* Children who are allergic or intolerant to sealant material\n* Children who cannot tolerate a dental suction isolation system, such as DryShield isolation\n* Children who do not complete a prophy cup polish.\n* Children who present with banded or bracketed molars\n* Patients or Parents who cannot fully understand an English or Spanish Consent\u002F Assent form.\n\nWithdrawal Criteria\n\n* Patients can withdraw voluntarily at any time.\n* Any tooth which has progression of caries beyond ICCMS Category 3 will be withdrawn from the study. These teeth will be treated with appropriate restorative dental treatment according to the standard of care.\n* Any qualifying tooth that subsequently requires a restoration due to trauma will be withdrawn from the study.\n* Any patient with an adverse reaction to treatment will be withdrawn. This event will be reported to the IRB.","5 Years",{"count":412,"type":21},217,[263],"Background: Sealants are a great tool in the prevention of caries in the pediatric population. It has been shown that up to 71% of occlusal decay is preventable after a single sealant application in a fissure, and thus is the standard of care due to difficulty for pediatric patients in hygiene, diet, and overall home care until manual dexterity increases.\n\nPurpose: This prospective randomized case control study aims to look at the longevity of sealants with bonding agent cured prior to sealant placement vs those with uncured bond. The study will be performed by USC graduate pediatric personnel.\n\nMethods: A split mouth prospective randomized control study will be performed on pediatric dental patients at Long Beach Memorial's Children's Dental Health Clinic and USC Pediatric Dental Clinic, placing sealants with cured bond on half of a mouth and sealants with uncured bond on the contralateral half. Intraoral photos will be obtained at the initial visit and recalls to evaluate the overall retention\u002Flongevity of the sealant placement. The goal of this study is determine which sealant has higher longevity and to provide recommendations for future pediatric dentists regarding sealant procedures.",[416,417],"Dental Sealant","Sealant Retention","2026-06-29",{"date":420,"type":30},"2026-07-02",{"date":422,"type":30},"2024-02-23",{"date":424,"type":21},"2027-06",{"name":36,"class":37},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":45,"sex":46,"minAge":74,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":321,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":65},"100641353","cochlear-implantation-and-social-outcomes-100641353","NCT07584837","Cochlear Implantation and Social Outcomes","Inclusion Criteria:\n\n* Age \\>= 60 years\n* English or Spanish speaking\n* older adults with bilateral moderate to profound sensorineural hearing loss who are candidates for cochlear implants or have undergone cochlear implantation.\n\nExclusion Criteria:\n\n* Age \\\u003C60 years\n* Unable to complete questionnaires in English or Spanish",{"count":157,"type":21},"The goal of this clinical trial is to learn if hearing devices, like cochlear implants, affect social and cognitive function of older adults. The main questions the researchers want to answer are:\n\n* How social are older adults with hearing loss before and after using hearing devices?\n* How well do older adults with hearing loss think before and after using hearing devices?\n* For older adults who have hearing loss and use hearing devices, do changes in social interaction explain changes in how well they think (cognitive function)?\n* Do brainwaves (EEGs) in older adults with hearing loss change after using hearing devices?\n* Are there differences in how social older adults with hearing loss are compared to older adults without hearing loss?\n\nWhat Participants Will Do:\n\n* Participants will take questionnaires for around 60 minutes. Questionnaires will ask participants about their background, health, hearing, and how social they are. Another set of questionnaires will check their thinking ability or cognition.\n* Participants will wear an audio sensor (TILES Audio Recorder on Jelly Mobile phone) for 2 weeks. The sensor will collect and store information about a participant's voice during conversations. Once the device has information about a participant's voice such as pitch and tone it will store this information and delete the audio recording. Words spoken during conversations will be deleted.\n* (Optional) Participants can choose to participate in a 45-60-minute EEG (electroencephalogram) recording session. Participants will have sensors placed on top of their heads. Sensors will record the participants' brainwaves. Sounds will be played to see how participants' brainwaves change when they hear sounds. Eligible participants will be invited to participate in 4-month follow-up study.",[435],"Hearing Loss, Bilateral Sensorineural",[437,438,439,440],"hearing loss","cochlear implant","social engagement","cognition","2026-06-17",{"date":443,"type":30},"2026-06-22",{"date":445,"type":21},"2027-07-01",{"date":447,"type":21},"2030-12-31",{"name":36,"class":37},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":45,"sex":46,"minAge":18,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":49,"phases":458,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":65},"100575593","evaluating-telehealth-delivery-of-brief-alcohol-screening-and-intervention-for-college-students-100575593","NCT06774300","Evaluating Telehealth Delivery of Brief Alcohol Screening and Intervention for College Students","Tele-BASICS","Inclusion Criteria:\n\n* between 18 and 26 years of age\n* fluent in understanding English\n* a registered student at one of the two intervention sites\n* adequate internet capabilities to support video-conferencing\n* access to a webcam, which is a standard features of most laptops, mobile devices, and desktops\n* engage in binge drinking (i.e., 4 or more standard drinks in a sitting for women or 5 or more standard drinks in a sitting for men) at least once in the past month (for the volunteer sample only)\n* experienced at least one negative alcohol-related consequence in the previous month (mandated students would meet this due to receiving an alcohol sanction)\n* reports a score of 2 or higher on questions about a) interest in reducing their drinking, or b) interest in not increasing their drinking.\n\nExclusion Criteria:\n\n* not meeting inclusion criteria or unwillingness to participate","26 Years",{"count":76,"type":21},[51],"This research study will test the efficacy of a telehealth version of the Brief Alcohol Screening and Intervention for College Students (BASICS), which is the gold standard prevention and intervention approach to target heavy alcohol use on college campuses across the United States.",[461],"Alcohol Consumption",[463,464,465,466],"alcohol","drinking","brief intervention","teleheath","2026-06-15",{"date":441,"type":30},{"date":470,"type":30},"2025-09-01",{"date":472,"type":21},"2030-07-31",{"name":36,"class":37},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":46,"minAge":482,"maxAge":483,"enrollmentInfo":484,"targetDuration":4,"studyType":49,"phases":486,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":65},"100456946","sensory-optimization-of-the-hospital-environment-100456946","NCT05230199","Sensory Optimization of the Hospital Environment","Multisensory Interventions to Improve Neurodevelopmental Outcomes of Preterm Infants Hospitalized in the Neonatal Intensive Care Unit","SOOTHE","Inclusion Criteria:\n\n* ≤ 32 weeks estimated gestational age (EGA)\n* recruited within the first week of life\n\nExclusion Criteria:\n\n* \\> 32 weeks EGA at birth\n* \\>7 days old\n* become wards of the state\n* have a suspected or confirmed congenital anomaly\n* face a high immediate threat of death, per the opinion of the attending physician.","1 Day","7 Days",{"count":485,"type":21},215,[51],"The long-term goal of this project is to improve the health and well-being of preterm infants and their parents. Although there is evidence to support positive multisensory interventions in the NICU, these interventions are often applied in an inconsistent manner, reducing their benefit. Through a rigorous and scientific process, we have developed a structured multisensory intervention program, titled Supporting and Enhancing NICU Sensory Experiences (SENSE), which includes specific doses and targeted timing of evidence-based interventions such as massage, auditory exposure, rocking, holding, and skin-to-skin care. The interventions are based on the infant's developmental stage and are adapted based on the infant's medical status and behavioral cues. The multisensory interventions are designed to be conducted during each day of NICU hospitalization by the parents, who are educated and supported to provide them. The proposed work aims to determine the effect of multisensory interventions on parent mental health, parent-child interaction, brain activity (amplitude integrated electroencephalography), and infant developmental outcomes through age 2 years, with specific attention to language outcome.",[489,490,491,492,493],"Preterm","Parent-Child Relations","Parents","Development, Infant","Sensory Integration Dysfunction",{"date":441,"type":30},{"date":496,"type":30},"2023-05-29",{"date":498,"type":21},"2028-12-31",{"name":36,"class":37},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":45,"sex":46,"minAge":18,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":49,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":321,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":65},"100641098","early-intervention-to-prevent-development-of-ptsd-in-burn-survivors-and-their-caregivers-100641098","NCT07656545","Early Intervention to Prevent Development of PTSD in Burn Survivors and Their Caregivers","Inclusion Criteria:\n\n* Alert, oriented, \\& not withdrawing from substance at time of screening\n* Can read and write in English\n* Hospitalized within 10 days of burn injury\n* Anticipated discharge \\\u003C=4 weeks\n* Have an email, mailing address, and at least 1 smart device for telehealth sessions\n* PTSD risk score of 2 or greater (patient-only)\n* Willing to attend therapy sessions with a loved one\n\nExclusion Criteria:\n\n* Currently incarcerated or in police custody\n* \\> 10 days post-burn\n* Lifetime diagnosis of primary psychosis or intellectual disability\n* Ongoing reported domestic violence in the dyad\n* Unstable bipolar disorder, severe substance use disorder, or acute suicidality with imminent intent that does not remit within 10 days of burn-injury\n* Inflammation Confounds (patient-only) of BMI \\> 40, metabolic syndrome, admission A1C of \\>= 6.5%\n* Currently receiving couples therapy",{"count":507,"type":21},44,[51],"The purpose of this clinical trial is to adapt and test a brief patient-caregiver early intervention designed to reduce posttraumatic stress symptoms in hospitalized burn patients and their caregivers. This intervention is a brief, 4-session cognitive-behavioral intervention designed for burn patients and their loved one to complete together, during and after hospitalization. The intervention targets relational communication and functioning through reduction of invalidating, negative statements and avoidant coping by teaching patients and their loved ones to engage in adaptive natural disclosures, supportive responses, and approach coping after the burn trauma. The intervention uses evidence-based psychotherapy techniques, including psychoeducation, motivational interviewing, and skills coaching. The clinical trial will occur in two sequential phases. In the first phase of the study (case series), the intervention will be provided to two burn patient-caregiver dyads (four adults) to pilot test the intervention, seek patient and provider feedback, and refine the intervention. All four adults will receive the intervention. In the second phase of the study, the randomized controlled trial (RCT) phase, investigators will enroll 20 more burn patient-caregiver dyads (40 more adults) who will be randomly assigned (like the flip of a coin) at the dyad level to receive the intervention or a burn survivor-only minimally enhanced usual care psychoeducation control condition (mEUC). The goals of the RCT phase are to study whether the intervention is acceptable to patients, feasible to conduct, and whether the intervention improves burn survivor-caregiver healthy relationship communication about difficult events and treatment outcomes compared to mEUC.",[511,512,513,514,515,516,517,518,519,520,521],"Posttraumatic Stress Disorder","Burns","Traumatic Injury","Acute Stress Disorder","Trauma and Stressor Related Disorders","Trauma and Stress Related Disorders","Stress Disorder","Stress Disorders, Post-Traumatic","Stress Disorders, Traumatic","Stress Disorders, Traumatic, Acute","Relationship, Social","2026-06-14",{"date":524,"type":30},"2026-06-18",{"date":526,"type":21},"2026-08-01",{"date":528,"type":21},"2029-02-28",{"name":36,"class":37},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":45,"sex":46,"minAge":236,"maxAge":155,"enrollmentInfo":537,"targetDuration":4,"studyType":49,"phases":539,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":321,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":545,"leadSponsor":547,"locationsCount":65},"100641145","impact-of-risk-feedback-on-behavioral-trajectories-100641145","NCT07657221","Impact of Risk Feedback on Behavioral Trajectories","Alcohol Metabolism and Disease Risk in Asians: Examining the Impact of Personalized Phenotypic\u002FGenotypic Feedback on Early Drinking Trajectories","Inclusion Criteria:\n\n* USC student of Chinese, Japanese, Korean, or Vietnamese heritage\n\nExclusion Criteria:\n\n* not a USC student, not 17-25 years old, not of Chinese, Japanese, Korean, or Vietnamese heritage",{"count":538,"type":21},450,[51],"The goal of this study is to examine the effects of providing personalized information about behavioral, physical, and genetic factors that are associated with elevations in risk for some health problems. The main research question is: can we affect young adult behaviors through communication about these health-related risks? Participants will be asked to complete an in-person baseline session where they provide a DNA sample, complete online surveys, and do a brief interview. They will then receive one of several brief online information sessions and be followed in online surveys approximately every 3 months over the next 2 years.",[542,461],"Healthy",{"date":524,"type":30},{"date":58,"type":21},{"date":546,"type":21},"2030-08-31",{"name":36,"class":37},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":134,"minAge":18,"maxAge":555,"enrollmentInfo":556,"targetDuration":4,"studyType":49,"phases":558,"briefSummary":559,"conditions":560,"keywords":4,"overallStatus":321,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":65},"100642254","energy-deficiency-on-hormones-in-contraceptive-users-100642254","NCT07651800","Energy Deficiency on Hormones in Contraceptive Users","Effects of a Modest Energy Deficit on Reproductive Hormones Across the Menstrual Cycle in Contraceptive Users","Inclusion Criteria:\n\n* Female, aged 18-35 years\n* Recreationally active (engaging in structured exercise between 8-15 hours per week)\n* BMI of 18.5-29.9 as a BMI below or above these cut points results in highly varied menstrual cycle lengths17\n* Not currently experiencing an eating disorder or disordered eating, or having a diagnosed eating disorder in the last 3 years\n* Non-pregnant or planning to become pregnant\n* Medically free from chronic diseases\n* Currently using one of the following contraceptive methods for ≥3 months:\n\nMonophasic oral contraceptive\n\n* Hormonal intrauterine device (H-IUD)\n* Copper intrauterine device\n* Weight stable (no weight change \\>5% body weight within the past 3 months)\n* Weight greater than or equal to 110 lbs\n* Not suffering from known gynecological disease (i.e., PCOS, endometriosis, etc.) that may influence menstrual cycle regularity\n* Willing and able to maintain current exercise habits throughout the study\n* Willing to follow study dietary guidance to achieve a \\~250 kcal\u002Fday energy deficit during Cycle 2\n\nExclusion Criteria:\n\n* Amenorrhea or oligomenorrhea\n* Perimenopausal or menopausal\n* Currently pregnant, planning pregnancy, or breastfeeding\n* Use of hormonal contraception other than monophasic oral contraceptives or hormonal IUD (implant, nuvaring, etc.)\n* Initiation or change of contraceptive method within the past 3 months\n* Diagnosis of polycystic ovary syndrome (PCOS), endometriosis, hypothalamic amenorrhea, or other known reproductive endocrine disorder\n* Current or history of eating disorder or clinically diagnosed disordered eating\n* Current participation in intentional weight loss or weight gain program\n* Use of medications known to affect metabolism or hormone levels (e.g., systemic corticosteroids, thyroid medications, insulin, GLP-1 agonists)\n* Known metabolic, cardiovascular, renal, hepatic, or endocrine disease\n* Musculoskeletal injury limiting exercise participation within the past 3 months\n* Smoking or nicotine use\n* Contraindications to DXA scanning (e.g., pregnancy, recent high-radiation diagnostic imaging exceeding institutional limits)\n* Inability or unwillingness to comply with study procedures","35 Years",{"count":557,"type":21},30,[51],"The purpose of the present study is to characterize the endocrine and metabolic responses to a modest, short-term energy deficiency (\\~250 kcal\u002Fday) across the menstrual cycle in recreationally active women using different contraceptive methods (oral contraceptive, hormonal IUD, and non-hormonal IUD). This study will leverage daily urinary hormone metabolite tracking and comprehensive metabolic assessments, providing foundational data addressing an important and previously unexamined interaction between energy availability and hormonal regulation in contraceptive users.",[561,562],"Energy Deficiency Due to Short-term Fasting","Hormonal Contraception","2026-06-10",{"date":565,"type":30},"2026-06-16",{"date":567,"type":21},"2026-09",{"date":569,"type":21},"2027-12",{"name":36,"class":37},{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":46,"minAge":18,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":49,"phases":579,"briefSummary":580,"conditions":581,"keywords":587,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":127},"100514906","personalized-health-self-management-training-for-colorectal-cancer-survivors-100514906","NCT05984589","Personalized Health Self-Management Training for Colorectal Cancer Survivors","A Prospective, Randomized, Controlled, Double-Arm Study of RISE (Re-Invent, Integrate, Strengthen, Expand) Personalized Self-Management Training (PSMT) Compared to Standardized Self-Management Training (SSMT) in Gastrointestinal Cancer (GI) Patients","Inclusion Criteria:\n\n* Age ≥18 years at the time of consent.\n* History of Stage I-IV colorectal cancer (CRC) or other gastrointestinal cancer within the past 10 years prior to enrollment.\n* Ability to speak, write, and read English sufficiently to allow for program participation.\n* Identified by self-report as having willingness and interest to work on at least one lifestyle-related risk factor. Lifestyle-related risk factors include diet, physical activity, body composition, alcohol use.\n* Scoring ≤3.5 on the World Cancer Research Fund\u002FAmerican Institute for Cancer Research (WCRF\u002FAICR) Health Behavior Adherence Scale or in the low-to-moderate range in any subcategory consistent with moderate to low adherence to healthy behavior recommendations (HBRs).\n* Ambulatory and independent in activities of daily living (ADL).\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Cognitive or mental impairments that in the opinion of the Principal Investigator or study physician would hinder the program participation.",{"count":182,"type":21},[51],"This is a Phase 2 prospective, randomized, controlled, double-arm study to assess personalized self-management training (PSMT) intervention efficacy and patient experiences compared to standardized self-management training (SSMT). A total of 120 gastrointestinal (GI) cancer patients will be enrolled and randomized 1:1 to complete a 6-week self-management training program (either PSMT or SSMT) to be carried out by licensed occupational therapists with doctoral training.\n\nThis study aims to examine whether PSMT is more effective in increasing adherence to healthy behavior recommendations compared to SSMT in GI cancer patients.",[582,583,584,585,586],"Colorectal Cancer","Healthy Lifestyle","Behavior, Health","Health Behavior","Gastrointestinal Cancers",[588],"self-management training","2026-06-08",{"date":563,"type":30},{"date":592,"type":30},"2024-03-01",{"date":594,"type":21},"2028-11-30",{"name":36,"class":37},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":46,"minAge":18,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":49,"phases":605,"briefSummary":606,"conditions":607,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":65},"100626066","personalized-ai-driven-models-in-cognitive-behavioral-therapy-for-anxiety-100626066","NCT07430800","Personalized AI-Driven Models in Cognitive Behavioral Therapy for Anxiety","SCH: Personalized AI-Driven Models for Supporting User Engagement and Adherence in Health Interventions: Validation in Cognitive Behavioral Therapy for Anxiety","Inclusion Criteria:\n\n* Are 18 years of age or older\n* Are university students\n* Are able to communicate in English\n* Have corrected-to-normal vision and hearing\n* Consent to have audio\u002Fvideo\u002Finteraction data recorded as part of the study\n* Have a GAD-7 (Generalized Anxiety Disorder-7 item) score of 5 or greater, indicating mild to elevated levels of self-reported symptoms of anxiety\n* Have a lower than minimal level of suicidality risk as measured by the Columbia Suicide Severity Rating Scale (C-SSRS) during screening (\"NO\" responses to items 3, 4, 5, and 6 on C-SSRS)\n* Having access to home WiFi\n\nExclusion Criteria:\n\n* Are less than 18 years of age\n* Are not university students\n* Are not able to communicate in English\n* Do not have corrected-to-normal vision and hearing\n* Do not consent to have audio\u002Fvideo\u002Finteraction data recorded as part of the study\n* Have a GAD-7 (Generalized Anxiety Disorder-7 item) score of 4 or lower.\n* Higher than a minimal level of suicidality risk as measured by the Columbia Suicide Severity Rating Scale (C-SSRS) during screening (\"YES\" responses to items 3, 4, 5, or 6 on C-SSRS)\n* Don't have access to home WiFi",{"count":604,"type":21},140,[51],"Untreated anxiety undermines long-term physical and emotional wellbeing, especially among college students, with rates worsening since the onset of the COVID-19 pandemic. Cognitive Behavioral Therapy (CBT) is the leading evidence-based intervention for anxiety, but many students fail to complete exercises between CBT sessions, reducing its effectiveness. Socially assistive robots (SARs) help promote adherence to home-based practice in the context of elder care, social skill learning, and physical therapy, but it is unknown how SARs can enhance CBT. The specific objective of this research is to develop personalized CBT SARs that can support CBT compliance for college students with anxiety. To meet the goals of the proposed work, these studies will determine how SAR personalization based on implicit and explicit feedback can help promote greater CBT compliance and anxiety reduction outcomes for students.",[608],"Generalized Anxiety Disorder (GAD)","2026-06-04",{"date":589,"type":30},{"date":612,"type":30},"2026-03-30",{"date":614,"type":21},"2028-08-15",{"name":36,"class":37},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":622,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":46,"minAge":335,"maxAge":624,"enrollmentInfo":625,"targetDuration":4,"studyType":49,"phases":627,"briefSummary":628,"conditions":629,"keywords":632,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":640,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":65},"100505899","using-indoor-air-filtration-to-slow-atherothrombosis-progression-in-adults-with-ischemic-heart-disease-history-100505899","NCT05867381","Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History","Slowing Atherothrombosis Progression Through Indoor Air Filtration: A Crossover Trial in Hispanic and Non-Hispanic Adults With Ischemic Heart Disease History","SAPIA","Inclusion Criteria:\n\n* Age between 65 and 84 years old;\n* Weight ≥ 110 pounds;\n* Nonsmokers for at least 1 year;\n* Have ischemic heart disease history, clinically stable for 6 months, without any deterioration in symptoms or episodes of angina based on past electronic medical records;\n* Both English and Spanish speaking participants will be included in the recruitment;\n* Live in the Los Angeles County.\n\nExclusion Criteria:\n\n* Have history of degenerative disease of the nervous system such as dementia and Alzheimer's;\n* Currently have active cancer treatments;\n* The residential house has already had HEPA filters;\n* Participants will move out from the current residential address in the next 2 years;\n* Participants will spend more than 1 month living outside the primary home;\n* Have any health conditions that prohibit collecting health and covariate data and biospecimens;\n* Participants' residential houses are not feasible for setting up air purifiers and air pollutants monitors.","84 Years",{"count":626,"type":21},112,[51],"This double-blind, randomized, crossover trial aims to test the hypothesis that longer-term indoor air filtration intervention can slow atherothrombosis progression by reducing indoor fine particulate matter (PM2.5) exposure in adults with ischemic heart disease history.",[630,631],"Air Pollution","Atherosclerosis",[633,634,635,636,631,637,638,639],"Air pollution","Particulate matter","Air purifier","HEPA filter","Ischemic Heart Disease","Thrombosis","Cardiovascular Disease",{"date":589,"type":30},{"date":642,"type":30},"2023-07-11",{"date":644,"type":21},"2028-06-30",{"name":36,"class":37},""]